Navigation Links
Alexion Reports Third Quarter 2008 Results
Date:10/23/2008

Continued Strong Uptake of Soliris(R) in U.S. and Europe

Reported Net Sales of $76.5 Million Include Recognition of $5.3 Million for Prior Quarter Shipments

Company Revises Revenue Guidance Upward and Expense Guidance Downward, and Forecasts GAAP Profit in Full Year 2008

Pipeline Progress in Hematology, Oncology, Transplant, Neurology

Third Quarter 2008 Financial Highlights:

-- Soliris(R) (eculizumab) net product sales of $76.5 million in Q3 2008 consisted of $71.2 million in net product sales for shipments that occurred in Q3 plus recognition of $5.3 million from net product sales associated with the decision of certain government payors during Q3 to reimburse for Soliris shipments that occurred in previous quarters.

-- Q3 GAAP net income was $19.7 million, or $0.23 per diluted share, compared to a GAAP net loss of $20.1 million, or $0.27 net loss per share, in Q3 2007.

-- Q3 non-GAAP net income was $25.7 million, or $0.29 per diluted share, compared to a non-GAAP net loss of $14.0 million, or $0.19 net loss per share, in Q3 2007. Q3 2008 non-GAAP net income, excluding the recognition of $5.3 million from prior-quarter shipments would be $20.8 million, or $0.23 per diluted share.

CHESHIRE, Conn., Oct. 23 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company," Nasdaq: ALXN) today announced financial results for the quarter ended September 30, 2008.

Third Quarter 2008 Financial Results:

For the three months ended September 30, 2008, Alexion reported total revenues of $76.5 million from net product sales of Soliris(R) (eculizumab), compared to total revenues of $21.8 million for the same period in 2007. The Q3 2008 revenues consisted of $71.2 million of net product sales from Soliris shipments during Q3, plus recognition of $5.3 million from net product sales associated with the Q3 2008 decision of certain government payors to reimburse for past Soliris shipment
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Alexion to Present at Bear Stearns Healthcare Conference
2. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
3. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
4. Alexion Reports Fourth Quarter and Full Year 2007 Results
5. Alexion Reports First Quarter 2008 Results
6. Notice of Time Change for Alexions Presentation at the Bank of America 2008 Health Care Conference
7. Alexion to Present at the William Blair 28th Annual Growth Stock Conference
8. Alexion to Present at the Jefferies & Co. 2nd Annual Healthcare Conference
9. Alexion Pharmaceuticals Invites You to Participate in its Second Quarter 2008 Results Conference Call and Web Cast
10. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... ... applications such as animal waste reduction, bioremediation, wastewater treatment, aquaculture and grease, ... announced today that it will be showcasing, ManureMagic™, its industry-leading product for ...
(Date:7/3/2015)... , July 3, 2015 ... till 22 september 2015 på  http://www.openinnovationinscience.at ... Innovation in Science" som hålls i ... en färsk undersökning med internationella forskare och ... (LBG) är hälsovetenskapens två största utmaningar bristen ...
(Date:7/2/2015)... , ... July 03, 2015 , ... Cuvettes have been used in countless labs for ... to find the cuvette they needed. As expected, this was a daunting and tiring ... wrong part because they were not able to navigate the complex catalog structure. , Now ...
(Date:7/2/2015)... ... ... Sleepless nights will become obsolete as Luzi , a sophisticated smart ... June 23. Sound sleepers and the sleep deprived both will love Luzi for its ... integration of the Bluetooth speaker, alarm clock and ability to charge various devices, including ...
Breaking Biology Technology:DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3New Cuvette E-Commerce Website Launched by FireflySci 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3
... industry seems to have taken a deep breath and a step back, getting ... were announced were mostly due to the overall economic difficulty facing the United ... ... the worst is past for health care, it does seem as though the ...
... spectacularly inefficient in their use of energy and materials, ... use of 20 major manufacturing processes. , Overall, new ... times bigger consumers of energy, per pound of output, ... making microchips uses up orders of magnitude more energy ...
... Warner Chilcott Limited (Nasdaq: WCRX ) announced ... submitted a New Drug Application for WC 3016, a ... Administration. About Warner Chilcott , Warner ... on the women,s healthcare and dermatology segments of the ...
Cached Biology Technology:The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health 3MIT: 'Alarming' use of energy in modern manufacturing methods 2MIT: 'Alarming' use of energy in modern manufacturing methods 3Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive 2Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive 3
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical ... use solutions, headquartered in Springville, Utah , ... California corporation with locations in Santa ... Rica ). This acquisition will incorporate MedConx,s ... ATL Technology,s existing facility in Costa Rica ...
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... for over half of vertebrate species, but while groups such ... by scientists for decades, knowledge about relationships among many types ... A team of scientists led by Richard Broughton, associate ... at the University of Oklahoma, published two studies that dramatically ...
... by simply feeding algae genetically engineered with a vaccine?, That,s ... after they demonstrated last May that algae can be engineered ... follow up study, published online today in the scientific journal ... Not yet, although the same method may work as a ...
... long been known that certain proteins, known as transcription ... read from DNA. As a result, it is ... underlie the mechanisms responsible for evolutionary adaptation. The ... an important part in evolutionary changes to animals, appearance ...
Cached Biology News:Something's fishy in the tree of life 2Quest for edible malarial vaccine leads to other potential medical uses for algae 2Quest for edible malarial vaccine leads to other potential medical uses for algae 3Quest for edible malarial vaccine leads to other potential medical uses for algae 4A surprising new function for small RNAs in evolution 2
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... pending) is a protein based inhibitor of ... the most common and troublesome RNases including ... SUPERaseIn can be used in any application ... is ideal for in vitro transcription and ...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
...
Biology Products: